In contrast to these strategies, which aim to reduce the negative impact of TGF-β on the anti-tumor response of CAR-T cells by inhibiting the expression of its receptor, other approaches are currently evaluating the therapeutic benefit of CAR-T cells modified to express a chimeric TGF-β receptor (switch receptor) whose activation by the cytokine would promote their functions (229). Here, TGFB1 is linked to neoplasm.